Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPP1CA | P62136 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TFPI2 | P48307 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18853812 | 0.88 | MEN1 (0.56) | KDM4ECYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14135618 | 0.84 | PPP1CA (0.49) | PPP1CALMNAKDM4ETFPI2GAA | |
| SCHEMBL9880156 | 0.84 | PPP1CA (0.49) | PPP1CALMNAKDM4ETFPI2GAA | |
| SCHEMBL2333833 | 0.84 | PPP1CA (0.49) | PPP1CALMNAKDM4ETFPI2GAA | |
| SCHEMBL3496527 | 0.78 | L3MBTL1 (0.67) | PPP1CALMNAKDM4EGAACYP1A2 | |
| SCHEMBL3496110 | 0.74 | GAA (0.71) | PPP1CALMNAKDM4EGAAHPGD | |
| SCHEMBL16838790 | 0.72 | MAOB (0.63) | — | |
| SCHEMBL13002108 | 0.72 | SIGMAR1 (0.45) | GAA | |
| SCHEMBL9880155 | 0.71 | MEN1 (0.54) | GAA | |
| SCHEMBL9291906 | 0.69 | MAOB (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | OAT, OGG1, OTC | PPP1CA 2763/4885LMNA 3922/4885KDM4E 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.